TCI GENE Inc. (TPEX:6879)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
33.25
-0.05 (-0.15%)
Mar 10, 2026, 1:34 PM CST
-36.67%
Market Cap 881.07M
Revenue (ttm) 324.73M
Net Income (ttm) 35.80M
Shares Out 26.46M
EPS (ttm) 1.35
PE Ratio 24.66
Forward PE n/a
Dividend 2.00 (5.57%)
Ex-Dividend Date Sep 5, 2025
Volume 4,225
Average Volume 6,788
Open 33.45
Previous Close 33.30
Day's Range 33.25 - 34.00
52-Week Range 32.45 - 59.00
Beta 0.17
RSI 34.53
Earnings Date Mar 12, 2026

About TCI GENE

TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services. It also provides precision prediction and personalized health management plans; and adipose-der... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6879
Full Company Profile

Financial Performance

In 2024, TCI GENE's revenue was 347.54 million, an increase of 4.10% compared to the previous year's 333.86 million. Earnings were 56.31 million, an increase of 382.40%.

Financial Statements

News

There is no news available yet.